New additions for two biotherapy monitoring kits are now available in all EU countries.

Theradiag (Marne-la-Vallée, France) a company specializing in theranostic and in vitro diagnostics, has obtained a CE mark for two new biotherapy monitoring kits; Tocilizumab (anti-IL6R) and Rituximab (anti-CD20) that further expand the Lisa Tracker range. The company now offers a range of seven blood test kits providing comprehensive multiparameter diagnosis solutions to monitor patients with autoimmune and inflammatory diseases. Rituximab is also used to treat hematological cancers.

Michel Finance, CEO of Theradiag, said, "These two new monitoring kits expand our theranostic range to cancerology and show that we are on track to meet our roadmap targets. The Lisa Tracker range is a unique diagnostic tool, which enables physicians to tailor treatments and optimize patient care. This new CE mark outlines our expert know-how in our lines of innovative proprietary diagnostic products and their sale in international markets.”

Theradiag innovates and develops theranostic tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer, and AIDS. Theradiag is thus participating in the development of "customized treatment,” which favors the individualization of treatments, the evaluation of their efficiency, and the prevention of drug resistance. The company markets the Lisa-Tracker range (CE marked), which is a comprehensive multiparameter diagnosis solution for patients with autoimmune diseases treated with biotherapies. Theradiag is also developing new diagnostic markers thanks to its microRNA platform, which will allow specific biomarkers to be identified in order to guide therapy and will be first applied to the treatment of AIDS.

Related Links:
Theradiag